Amgen and Cytokinetics omecamtiv mecarbil Phase II trial shows positive results in chronic heart failure

A Phase II study of omecamtiv mecarbil from Amgen (Nasdaq: AMGN) and Cytokinetics showed significant improvements in cardiac function among patients with chronic heart failure.

The study was the expansion phase of the COSMIC-HF study and took in 448 patients with chronic heart failure and left ventricular systolic dysfunction. Patients were randomized to treatment with an oral formulation of omecamtiv mecarbil twice daily or placebo for 20 weeks and followed for 24 weeks.

The primary endpoints were assessing the maximum and pre-dose plasma concentrations of omecamtiv mecarbil, while secondary endpoints included changes from baseline in systolic ejection time, stroke volume, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, heart rate and N-terminal pro-brain natriuretic peptide levels at 20 weeks.